BioNTechBNTX
About: BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.
Employees: 6,133
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
39% more call options, than puts
Call options by funds: $373M | Put options by funds: $269M
27% more first-time investments, than exits
New positions opened: 62 | Existing positions closed: 49
10% more capital invested
Capital invested by funds: $5.25B [Q3] → $5.78B (+$535M) [Q4]
2.71% more ownership
Funds ownership: 18.63% [Q3] → 21.34% (+2.71%) [Q4]
1% more funds holding
Funds holding: 294 [Q3] → 297 (+3) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q3] → 7 (+0) [Q4]
2% less repeat investments, than reductions
Existing positions increased: 83 | Existing positions reduced: 85
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Truist Securities Asthika Goonewardene 32% 1-year accuracy 8 / 25 met price target | 58%upside $172 | Buy Initiated | 10 Jan 2025 |
Wells Fargo Mohit Bansal 63% 1-year accuracy 17 / 27 met price target | 56%upside $170 | Overweight Initiated | 11 Dec 2024 |
Financial journalist opinion
Based on 7 articles about BNTX published over the past 30 days
